Key statistics
Short selling activityProvided by S&P Global Market Intelligence
| Open | 5.18 |
|---|---|
| High | 5.18 |
| Low | 5.18 |
| Bid | 5.11 |
| Offer | 5.14 |
| Previous close | 5.18 |
| Average volume | -- |
|---|---|
| Shares outstanding | 307.07m |
| Free float | 301.81m |
| P/E (TTM) | 59.82 |
| Market cap | 1.70bn USD |
| EPS (TTM) | 0.0926 USD |
Data delayed at least 15 minutes, as of Jul 31 2024.
More ▼
- MannKind to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
- MannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
- MannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza® for Youth with Newly-Diagnosed Type 1 Diabetes (T1D)
- MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy
- MannKind Provides Business Updates and 2026 Growth Drivers
- MannKind Shares FUROSCIX® Business Updates
- MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease
- MannKind to Present at the Jefferies Global Healthcare Conference
- MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease
- MannKind Commemorates Alfred E. Mann’s 100th Birthday with New Scholarship Program Supporting Young Adults Living with Diabetes
More ▼
